HRP20180903T1 - Mimetici kalcitonina za liječenje bolesti i poremećaja - Google Patents
Mimetici kalcitonina za liječenje bolesti i poremećaja Download PDFInfo
- Publication number
- HRP20180903T1 HRP20180903T1 HRP20180903TT HRP20180903T HRP20180903T1 HR P20180903 T1 HRP20180903 T1 HR P20180903T1 HR P20180903T T HRP20180903T T HR P20180903TT HR P20180903 T HRP20180903 T HR P20180903T HR P20180903 T1 HRP20180903 T1 HR P20180903T1
- Authority
- HR
- Croatia
- Prior art keywords
- calcitonin mimetic
- reducing
- calcitonin
- undesirably high
- treatment
- Prior art date
Links
- 102000055006 Calcitonin Human genes 0.000 title claims 17
- 108060001064 Calcitonin Proteins 0.000 title claims 17
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title claims 17
- 229960004015 calcitonin Drugs 0.000 title claims 17
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 210000002966 serum Anatomy 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000036528 appetite Effects 0.000 claims 2
- 235000019789 appetite Nutrition 0.000 claims 2
- 238000007446 glucose tolerance test Methods 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (8)
1. Mimetik kalcitonina za primjenu kao lijek, pri čemu taj mimetik kalcitonina je:
2. Mimetik kalcitonina za primjenu u liječenju dijabetesa tipa I, dijabetesa tipa II ili metaboličkog sindroma, pretilosti, ili za suzbijanje apetita, ili za ublažavanje otpornosti na inzulin, ili za smanjenje nepoželjno visoke razine glukoze u serumu pri izgladnjivanju, ili za smanjenje nepoželjno visoke razine vršne vrijednosti glukoze u serumu, ili za smanjenje nepoželjno visoke razine vršne vrijednosti inzulina u serumu, ili za smanjenje nepoželjno velikog odgovora na test tolerancije na glukozu, ili za liječenje osteoporoze, ili za liječenje osteoartritisa, pri čemu je mimetik kalcitonina:
3. Mimetik kalcitonina za primjenu sukladno patentnom zahtjevu 2, pri čemu je mimetik kalcitonina za primjenu u liječenju dijabetesa tipa I, dijabetesa tipa II, ili metaboličkog sindroma.
4. Mimetik kalcitonina za primjenu sukladno patentnom zahtjevu 2, pri čemu je mimetik kalcitonina za primjenu u liječenju pretilosti.
5. Mimetik kalcitonina za primjenu sukladno patentnom zahtjevu 2, pri čemu je mimetik kalcitonina za primjenu radi suzbijanja apetita.
6. Mimetik kalcitonina za primjenu sukladno patentnom zahtjevu 2, pri čemu je mimetik kalcitonina za primjenu u ublažavanju otpornosti na inzulin.
7. Mimetik kalcitonina za za primjenu sukladno patentnom zahtjevu 2, pri čemu je mimetik kalcitonina za primjenu u smanjenju nepoželjno visoke razine glukoze u seruma poslije izgladnjivanja, ili za smanjenje nepoželjno visoke razine vršne vrijednosti glukoze u serumu, ili za smanjenje nepoželjno visoke razine vršne vrijednosti insulina u serumu, ili za smanjenje nepoželjno velikog odgovora na test tolerancije na glukozu.
8. Mimetik kalcitonina za za primjenu sukladno patentnom zahtjevu 2, pri čemu je mimetik kalcitonina za primjenu u liječenje osteoporoze ili osteoartritisa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161554771P | 2011-11-02 | 2011-11-02 | |
| US201161578620P | 2011-12-21 | 2011-12-21 | |
| EP16174260.6A EP3095484B1 (en) | 2011-11-02 | 2012-11-02 | Calcitonin mimetics for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180903T1 true HRP20180903T1 (hr) | 2018-08-24 |
Family
ID=51266018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180903TT HRP20180903T1 (hr) | 2011-11-02 | 2018-06-11 | Mimetici kalcitonina za liječenje bolesti i poremećaja |
Country Status (12)
| Country | Link |
|---|---|
| EP (3) | EP2773365B1 (hr) |
| CY (1) | CY1120332T1 (hr) |
| DK (2) | DK3095484T3 (hr) |
| ES (2) | ES2586805T3 (hr) |
| HR (1) | HRP20180903T1 (hr) |
| HU (1) | HUE039105T2 (hr) |
| LT (1) | LT3095484T (hr) |
| PL (1) | PL3095484T3 (hr) |
| PT (1) | PT3095484T (hr) |
| RS (1) | RS57519B1 (hr) |
| SI (1) | SI3095484T1 (hr) |
| TR (1) | TR201808456T4 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201704429D0 (en) * | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| US4764589A (en) * | 1987-05-26 | 1988-08-16 | Rorer Pharmaceutical Corporation | [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin |
| US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
| US5102666A (en) | 1990-09-11 | 1992-04-07 | Oramed, Inc. | Calcium polycarbophil controlled release composition and method |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6692766B1 (en) | 1994-06-15 | 2004-02-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Controlled release oral drug delivery system |
| US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
| US5773647A (en) | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| ATE522598T1 (de) | 1997-04-16 | 2011-09-15 | Unigene Lab Inc | Direkte expression von peptiden in nährmedien |
| EP1137431A1 (en) | 1998-12-04 | 2001-10-04 | Provalis UK Limited | Pharmaceutical compositions containing insulin |
| ATE288415T1 (de) | 1999-04-05 | 2005-02-15 | Emisphere Tech Inc | Dinatrium-salze, monohydrate und ethanol-solvate |
| US6780846B1 (en) | 1999-09-27 | 2004-08-24 | Elan Corporation, Plc | Membrane translocating peptide drug delivery system |
| GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
| US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
| US7316819B2 (en) | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
| US6770625B2 (en) | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| ES2665464T3 (es) | 2003-03-28 | 2018-04-25 | Sigmoid Pharma Limited | Forma de dosificación oral sólida que contiene microcápsulas sin costuras |
| GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
| TWI343816B (en) | 2003-07-23 | 2011-06-21 | Novartis Ag | Use of calcitonin in osteoarthritis |
| AU2004317954A1 (en) | 2003-09-17 | 2005-10-13 | Chiasma, Inc. | Compositions capable of facilitating penetration across a biological barrier |
| CN101035547A (zh) | 2004-07-22 | 2007-09-12 | 蒂奥迈里克斯研究与指导有限公司 | 含巯基化合物作为流出泵抑制剂的用途 |
| GB0422644D0 (en) * | 2004-10-12 | 2004-11-10 | Novartis Ag | Organic compounds |
| US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
| WO2007002532A2 (en) | 2005-06-24 | 2007-01-04 | Unigene Laboratories, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
| US9259456B2 (en) | 2005-09-06 | 2016-02-16 | Oramed Pharmaceuticals Inc. | Methods and compositions for oral administration of proteins |
| US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
| PT1834635E (pt) | 2006-03-13 | 2011-10-13 | Advanced In Vitro Cell Technologies S L | Sistemas estáveis de nanocápsula para a administração de moléculas activas |
| BRPI0710503A2 (pt) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| BRPI1006943A2 (pt) * | 2009-01-22 | 2021-06-15 | Unigene Laboratories Inc. | peptídeo, composição farmacêutica que compreende o peptídeo e método para supressão do apetite, prevenção ou tratamento de uma condição de sobrepeso ou obesidade, ou para tratar diabetes |
| US20120046224A1 (en) * | 2009-03-12 | 2012-02-23 | Nordic Bioscience A/S | Treatment of diabetes and metabolic syndrome |
-
2012
- 2012-11-02 EP EP12846423.7A patent/EP2773365B1/en not_active Not-in-force
- 2012-11-02 ES ES12846423.7T patent/ES2586805T3/es active Active
- 2012-11-02 PL PL16174260T patent/PL3095484T3/pl unknown
- 2012-11-02 TR TR2018/08456T patent/TR201808456T4/tr unknown
- 2012-11-02 LT LTEP16174260.6T patent/LT3095484T/lt unknown
- 2012-11-02 ES ES16174260.6T patent/ES2673617T3/es active Active
- 2012-11-02 RS RS20180695A patent/RS57519B1/sr unknown
- 2012-11-02 EP EP16174260.6A patent/EP3095484B1/en active Active
- 2012-11-02 DK DK16174260.6T patent/DK3095484T3/en active
- 2012-11-02 HU HUE16174260A patent/HUE039105T2/hu unknown
- 2012-11-02 DK DK12846423.7T patent/DK2773365T3/en active
- 2012-11-02 PT PT161742606T patent/PT3095484T/pt unknown
- 2012-11-02 SI SI201231314T patent/SI3095484T1/en unknown
- 2012-11-02 EP EP18161594.9A patent/EP3357540A1/en not_active Withdrawn
-
2018
- 2018-06-11 HR HRP20180903TT patent/HRP20180903T1/hr unknown
- 2018-06-14 CY CY20181100625T patent/CY1120332T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3357540A1 (en) | 2018-08-08 |
| RS57519B1 (sr) | 2018-10-31 |
| EP3095484A1 (en) | 2016-11-23 |
| SI3095484T1 (en) | 2018-08-31 |
| ES2586805T3 (es) | 2016-10-19 |
| EP2773365A1 (en) | 2014-09-10 |
| EP3095484B1 (en) | 2018-05-02 |
| EP2773365B1 (en) | 2016-07-20 |
| ES2673617T3 (es) | 2018-06-25 |
| LT3095484T (lt) | 2018-08-10 |
| HUE039105T2 (hu) | 2018-12-28 |
| DK2773365T3 (en) | 2016-08-29 |
| CY1120332T1 (el) | 2019-07-10 |
| PL3095484T3 (pl) | 2018-10-31 |
| DK3095484T3 (en) | 2018-06-25 |
| TR201808456T4 (tr) | 2018-07-23 |
| EP2773365A4 (en) | 2015-05-20 |
| PT3095484T (pt) | 2018-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY176863A (en) | Ibat inhibitors for treatment of metabolic disorders and related conditions | |
| BR112013018782A2 (pt) | compostos e seus efeitos no comportamento alimentar | |
| BR112015007685A2 (pt) | derivados de exendina-4 como agonistas duplos de glp1/glucagon | |
| BR112015014800A2 (pt) | derivados da exendina-4 funcionalizada | |
| CL2008000067A1 (es) | Compuestos derivados de espirocromanona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el sindrome metabolico, higado graso, hiperlipemia, obesidad, diabetes, bulimia, neoplasma maligno o enfermedades infecciosas. | |
| HRP20180903T1 (hr) | Mimetici kalcitonina za liječenje bolesti i poremećaja | |
| JP2013525444A5 (hr) | ||
| EA201590011A1 (ru) | Пептидные аналоги эксендина-4 | |
| MX344925B (es) | Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas. | |
| EP3016527A4 (en) | Treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimer's disease and inflammatory bowel disease by using at least one bacterial strain from prevotella | |
| BR112012018703A2 (pt) | compostos e seus efeitos sobre o comportamento alimentar | |
| EP2621282A4 (en) | GABA AGONISTS FOR THE TREATMENT OF DISEASES RELATED TO THE METABOLIC SYNDROME AND GABA COMBINATIONS FOR THE TREATMENT OR PROPHYLAXIS OF DIABETES TYPE I | |
| MX2011013173A (es) | Peptidos especificos para receptores de melanocortina. | |
| CL2013002973A1 (es) | Compuestos derivados de esteres de fenilglucopiranosil sustituidos mediadores del co-transportador sodio/d-glucosa (sglt); composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento del sindrome metabolico, sindrome x, diabetes, resistencia a la insulina, entre otros | |
| BR112013029062A2 (pt) | lixisenatida e metformina para o tratamento de diabetes tipo 2 | |
| EA201391028A1 (ru) | Гиполипидемическое противодиабетическое средство | |
| JP2014501492A5 (hr) | ||
| MX351092B (es) | Analogos peptidicos para tratar enfermedades y trastornos. | |
| JP2011246355A5 (hr) | ||
| WO2008115390A3 (en) | Methods of using defensins to treat diabetes | |
| JP2014031330A5 (hr) | ||
| WO2007009704A3 (en) | Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes | |
| Lu | Zoledronic acid | |
| Finn | Metabolic Syndrome Linked to Earlier Strokes | |
| 石田紀子 | Development of the theory of transportability and its application to risk assessment of metabolic syndrome |